Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zai Lab (ZLAB – Research Report), NeuroPace (NPCE – Research Report) and CervoMed (CRVO – Research ...

Zai Lab Ltd (ZLAB) reports impressive revenue growth and improved net loss, with a strategic focus on global pipeline ...

Zai Lab Ltd ( (ZLAB)) has released its Q3 earnings. Here is a breakdown of the information Zai Lab Ltd presented to its investors. Zai Lab Limited is a biopharmaceutical company based in China and the ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Zai Lab (NASDAQ:ZLAB) stock rose 5% in early trading Monday after the company announced that Vyvgart Hytrulo’s regulatory ...

Shares of NASDAQ:ZLAB opened at $30.62 on Monday. The business’s 50 day simple moving average is $25.16 and its 200 day ...

Zai Lab Limited Unsponsored ADR (ZLAB) reported $102.27 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 47.7%. EPS of -$0.42 for the same period ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...

Zai Lab Limited (NASDAQ: ZLAB) and argenx (NASDAQ: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for ...

Zai Lab (ZLAB) reported topline data from a Phase 3 study for KarXT in the treatment of schizophrenia, with plans to file for approval in China in early 2025. Read more here.

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will hold an investor webcast to discuss data from a Phase 1 clinical trial of ZL-1 ...